## Alessandra Lafranconi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4591449/publications.pdf

Version: 2024-02-01

92 papers 25,496 citations

32 h-index 90 g-index

92 all docs 92 docs citations 92 times ranked 42114 citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
3	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
4	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	4.9	2,625
5	Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	4.9	2,005
6	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716
7	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
8	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	6.3	294
9	Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. Lancet, The, 2018, 391, 1783-1798.	6.3	172
10	Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget, 2017, 8, 35376-35389.	0.8	162
11	Fruit and vegetable consumption and health outcomes: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2019, 70, 652-667.	1.3	156
12	Microbiota effects on cancer: from risks to therapies. Oncotarget, 2018, 9, 17915-17927.	0.8	155
13	A Review of the Mycotoxin Enniatin B. Frontiers in Public Health, 2017, 5, 304.	1.3	100
14	Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. Oncotarget, 2017, 8, 24401-24414.	0.8	99
15	Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard. Oncologist, 2011, 16, 1258-1269.	1.9	92
16	Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment. Nutrients, 2017, 9, 210.	1.7	91
17	Whole grain consumption and human health: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2020, 71, 668-677.	1.3	81
18	Dairy foods and health: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2020, 71, 138-151.	1.3	74

#	Article	IF	CITATIONS
19	Serum Markers of Intrahepatic Cholangiocarcinoma. Disease Markers, 2013, 34, 219-228.	0.6	64
20	Epstein-Barr Virus– and Kaposi Sarcoma-Associated Herpesvirus–Related Malignancies in the Setting of Human Immunodeficiency Virus Infection. Seminars in Oncology, 2015, 42, 258-271.	0.8	60
21	Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget, 2017, 8, 14192-14220.	0.8	60
22	Lead Poisoning: Historical Aspects of a Paradigmatic "Occupational and Environmental Disease― Safety and Health at Work, 2012, 3, 11-16.	0.3	59
23	Therapeutic approaches to AIDS-related malignancies. Oncogene, 2003, 22, 6646-6659.	2.6	56
24	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biology and Therapy, 2016, 17, 1213-1220.	1.5	52
25	B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget, 2018, 9, 24837-24856.	0.8	44
26	NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 7802.	1.8	42
27	Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. Oncotarget, 2017, 8, 30606-30616.	0.8	40
28	Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. Pharmacoeconomics, 2018, 36, 567-589.	1.7	39
29	Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study. Frontiers in Oncology, 2020, 10, 594.	1.3	39
30	Nut and legume consumption and human health: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2021, 72, 871-878.	1.3	39
31	Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormoneâ€Responsive Human Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2063-2074.	2.0	38
32	The socioeconomic burden of patients affected by hemophilia with inhibitors. European Journal of Haematology, 2018, 101, 435-456.	1.1	37
33	Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). Oncology Reports, 2016, 36, 603-612.	1.2	34
34	Clinical Presentation and Outcome of Colorectal Cancer in HIV-Positive Patients: A Clinical Case-Control Study. Onkologie, 2009, 32, 319-324.	1.1	32
35	Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anti-Cancer Drugs, 2013, 24, 212-218.	0.7	32
36	Coffee Decreases the Risk of Endometrial Cancer: A Dose–Response Meta-Analysis of Prospective Cohort Studies. Nutrients, 2017, 9, 1223.	1.7	32

#	Article	IF	Citations
37	Coffee Intake Decreases Risk of Postmenopausal Breast Cancer: A Dose-Response Meta-Analysis on Prospective Cohort Studies. Nutrients, 2018, 10, 112.	1.7	32
38	Egg consumption and human health: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2020, 71, 325-331.	1.3	32
39	Intensive follow-up for women with breast cancer: review of clinical, economic and patient's preference domains through evidence to decision framework. Health and Quality of Life Outcomes, 2017, 15, 206.	1.0	31
40	A New Proposal for the Pathogenic Mechanism of Non-Coeliac/Non-Allergic Gluten/Wheat Sensitivity: Piecing Together the Puzzle of Recent Scientific Evidence. Nutrients, 2017, 9, 1203.	1.7	28
41	Total, red and processed meat consumption and human health: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2022, 73, 726-737.	1.3	28
42	Caffeinated and decaffeinated coffee consumption and melanoma risk: a dose-response meta-analysis of prospective cohort studies. International Journal of Food Sciences and Nutrition, 2018, 69, 417-426.	1.3	26
43	Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment. Neuroradiology Journal, 2018, 31, 18-26.	0.6	24
44	FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study. Archives of Gerontology and Geriatrics, 2011, 52, 89-93.	1.4	23
45	Current and Emerging Treatments for Metastatic Renal Cell Carcinoma. Current Cancer Drug Targets, 2018, 18, 468-479.	0.8	23
46	Endocrine disruptors and female cancer: Informing the patients (Review). Oncology Reports, 2015, 34, 3-11.	1.2	22
47	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Oncotarget, 2016, 7, 85641-85649.	0.8	22
48	Costs and effectiveness of influenza vaccination: a systematic review. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 49-57.	0.2	22
49	Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis. Oncotarget, 2017, 8, 17383-17395.	0.8	21
50	Exploring the molecular aspects associated with testicular germ cell tumors: a review. Oncotarget, 2018, 9, 1365-1379.	0.8	21
51	Serum and tissue markers in colorectal cancer: State of art. Critical Reviews in Oncology/Hematology, 2017, 111, 103-116.	2.0	20
52	Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model. International Journal of Molecular Sciences, 2020, 21, 3479.	1.8	20
53	Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection. Current HIV Research, 2010, 8, 218-222.	0.2	19
54	The role of diet in gastric cancer: still an open question. Frontiers in Bioscience - Landmark, 2012, 17, 1640.	3.0	19

#	Article	IF	Citations
55	The role of nutrition in the development of esophageal cancer: what do we know?. Frontiers in Bioscience - Elite, 2012, E4, 351.	0.9	18
56	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncology, 2015, 11, 3091-3098.	1.1	17
57	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget, 2016, 7, 37487-37497.	0.8	16
58	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget, 2015, 6, 28716-28730.	0.8	14
59	Colorectal Cancer in Elderly Patients: From Best Supportive Care to Cure. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1332-1343.	0.9	14
60	Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions. Pharmacoeconomics, 2018, 36, 263-284.	1.7	13
61	Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies. Oncotarget, 2018, 9, 20807-20815.	0.8	13
62	Bevacizumab plus Irinotecan-, Fluorouracil-, and Leucovorin-Based Chemotherapy with Concomitant HAART in an HIV-Positive Patient with Metastatic Colorectal Cancer. Onkologie, 2008, 31, 394-397.	1.1	10
63	Optimal Management of Prostate Cancer Based on its Natural Clinical History. Current Cancer Drug Targets, 2018, 18, 457-467.	0.8	10
64	Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1344-1353.	0.9	10
65	Biomarkers in neuroendocrine tumors. Frontiers in Bioscience - Scholar, 2010, S2, 332-342.	0.8	9
66	Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). Archives of Gerontology and Geriatrics, 2012, 55, 271-275.	1.4	9
67	The short-term effect of particulate matter on cardiorespiratory drug prescription, as a proxy of mild adverse events. Environmental Research, 2017, 157, 145-152.	3.7	9
68	First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 441.	1.6	9
69	Is It Possible a Conservative Approach After Radiochemotherapy in Locally Advanced Rectal Cancer (LARC)? A Systematic Review of the Literature and Meta-analysis. Journal of Gastrointestinal Cancer, 2019, 50, 98-108.	0.6	9
70	Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors. Cells, 2019, 8, 522.	1.8	8
71	Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. Oncologist, 2020, 25, e1254-e1254.	1.9	8
72	Fish and human health: an umbrella review of observational studies. International Journal of Food Sciences and Nutrition, 2022, 73, 851-860.	1.3	8

#	Article	IF	CITATIONS
73	Adjuvant Treatment of High-risk Adult Soft Tissue Sarcomas: A Survey by the Italian Sarcoma Group. Tumori, 2006, 92, 92-97.	0.6	7
74	FOLFOX-4 Regimen with Concomitant Highly Active Antiretroviral Therapy in Metastatic Colorectal Cancer HIV-Infected Patients: A Report of Five Cases and Review of the Literature. Cancer Investigation, 2008, 26, 610-614.	0.6	7
75	Cardiorespiratory treatments as modifiers of the relationship between particulate matter and health: A case-only analysis on hospitalized patients in Italy. Environmental Research, 2015, 136, 491-499.	3.7	7
76	New treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy. Expert Opinion on Pharmacotherapy, 2016, 17, 2391-2403.	0.9	7
77	Increased risk of testis failure in testicular germ cell tumor survivors undergoing radiotherapy. Oncotarget, 2018, 9, 3060-3068.	0.8	7
78	Unusual Presentation of Metastatic Hepatocellular Carcinoma in an HIV/HCV Coinfected Patient: Case Report and Review of the Literature. Tumori, 2008, 94, 589-591.	0.6	6
79	Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors. Oncotarget, 2018, 9, 35251-35265.	0.8	6
80	Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report. Frontiers in Oncology, 2020, 10, 232.	1.3	5
81	Medical leadershipâ€"from inspiration to education. Lancet, The, 2015, 386, 1531-1532.	6.3	4
82	Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review. Current Cancer Drug Targets, 2018, 18, 405-409.	0.8	4
83	Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature. Tumori, 2008, 94, 589-91.	0.6	4
84	â€`Du bist was du isst': challenges in European nutrition policy. European Journal of Public Health, 2017, 27, 26-31.	0.1	3
85	Nutrition in oncologic patients during antiblastic treatment. Frontiers in Bioscience - Landmark, 2013, 18, 120.	3.0	2
86	Capecitabine cardiotoxicity: How to limit life-threatening events. International Journal of Cardiology, 2017, 229, 5.	0.8	2
87	Management of pregnancy blood pressure increase in the emergency room: role of PIGF-based biochemical markers and relative economic impact. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 1083-1090.	0.7	2
88	How best to use the EXPO momentum to improve our food environment?. European Journal of Public Health, 2015, 25, 751-752.	0.1	1
89	Editorial: Public Health Nutrition: Assessing Evidence to Determine Policy and Practice. Frontiers in Public Health, 2019, 7, 21.	1.3	1
90	Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. Anticancer Research, 2015, 35, 2391-9.	0.5	1

#	Article	IF	CITATIONS
91	Occult Small Cell Lung Cancer Associated with Paraneoplastic Neurologic Syndrome: Case Report. Tumori, 2001, 87, 447-450.	0.6	О
92	Choosing Wisely Recommendations Using Administrative Claims Data. JAMA Internal Medicine, 2016, 176, 565.	2.6	0